Matthias Eiber
Technische Universität München
9 Papers
82 Citations
Matthias Eiber is an academic researcher from Technische Universität München. The author has contributed to research in topics: Medicine & Prostatectomy. The author has an hindex of 7, co-authored 9 publications.
Chat about Author
Papers
68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging
Christoph Rischpler,Christoph Rischpler,Teresa Beck,Shozo Okamoto,Shozo Okamoto,Anna Melissa Schlitter,Karina Knorr,Markus Schwaiger,Jürgen E. Gschwend,Tobias Maurer,Tobias Maurer,Philipp T. Meyer,Matthias Eiber +12 more
TL;DR: The study investigates the presence of physiologic prostate-specific membrane antigen uptake on PET in cervical, celiac, and sacral ganglia of the sympathetic trunk as a pitfall for lymph node metastases in prostate cancer imaging and finds the level of 68Ga-PSMA-ligand uptake seems to be patient-related.
122
Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation
Lale Umutlu,Thomas Beyer,Johannes Grueneisen,Christoph Rischpler,Harald H. Quick,Patrick Veit-Haibach,Matthias Eiber,Sandra Purz,Gerald Antoch,Sergios Gatidis,Konstantin Nikolaou,Jürgen F. Schaefer,Ivo Rausch,Ken Herrmann,Vorstand der Interdisziplinären Ag für Hybride Bildgebung in alphabetischer Reihenfolge,Vorstand der Deutschen Röntgengesellschaft in alphabetischer Reihenfolge +15 more
TL;DR: This document summarizes consensus recommendations on key aspects of patient referral and preparation, PET/MRI workflow and imaging protocols, as well as reporting strategies for whole-body [18F]-FDG-PET/MRI for Oncology.
Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging?
Tobias Maurer,Ambros J Beer,Hans-Jürgen Wester,Hubert Kübler,Markus Schwaiger,Matthias Eiber +5 more
TL;DR: Based on the first clinical results, 68 Ga-PSMA-L PET/MRI is described as a novel imaging technique for patients with PCa at different disease stages, and potential future applications are discussed.
26
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
Ann-Kathrin Oehus,Stephanie G. C. Kroeze,Nina-Sophie Schmidt-Hegemann,Marco M. E. Vogel,Simon Kirste,Simon Kirste,J. Becker,Irene A. Burger,Thorsten Derlin,Peter Bartenstein,Matthias Eiber,Michael Mix,Christian la Fougère,Claus Belka,Claus Belka,Stephanie E. Combs,Anca-Ligia Grosu,Anca-Ligia Grosu,Arndt-Christian Müller,Matthias Guckenberger,Hans Christiansen,Christoph Henkenberens +21 more
TL;DR: RT as MDT based on PSMA - PET of all metastases of recurrent prostate cancer after RP and sRT represents a viable treatment option for well-informed and well-selected patients.
Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy—a multicenter retrospective study
N-S Schmidt-Hegemann,Stephanie G. C. Kroeze,Christoph Henkenberens,Marco M. E. Vogel,Simon Kirste,J. Becker,Irene A. Burger,Thorsten Derlin,Peter Bartenstein,Matthias Eiber,Michael Mix,Christian la Fougère,Arndt-Christian Müller,Anca-L. Grosu,Stephanie E. Combs,Stephanie E. Combs,Hans Christiansen,Matthias Guckenberger,Claus Belka +18 more
TL;DR: Overall, BRFS was dependent on patterns of metastatic disease, and MDR of PSMA PET-positive oligo-metastases can be offered considering that about one-third of the patients progressed within a median follow-up of 16 months.
19